Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Equity (2018 - 2025)

UroGen Pharma (URGN) has disclosed Return on Equity for 8 consecutive years, with 1.39% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 1657.0% year-over-year to 1.39%, compared with a TTM value of 1.39% through Dec 2025, up 1657.0%, and an annual FY2025 reading of 2.69%, down 74.0% over the prior year.
  • Return on Equity was 1.39% for Q4 2025 at UroGen Pharma, down from 1.58% in the prior quarter.
  • Across five years, Return on Equity topped out at 26.16% in Q1 2022 and bottomed at 15.18% in Q4 2024.
  • Average Return on Equity over 5 years is 2.17%, with a median of 1.41% recorded in 2025.
  • The sharpest move saw Return on Equity surged 2751bps in 2022, then plummeted -2507bps in 2023.
  • Year by year, Return on Equity stood at 5.55% in 2021, then skyrocketed by 126bps to 1.44% in 2022, then soared by 33bps to 1.91% in 2023, then plummeted by -896bps to 15.18% in 2024, then surged by 109bps to 1.39% in 2025.
  • Business Quant data shows Return on Equity for URGN at 1.39% in Q4 2025, 1.58% in Q3 2025, and 2.22% in Q2 2025.